2018

20/12/2018 Mayne Pharma extends debt facility and adds receivables facility

17/12/2018 Mayne Pharma announces US commercial rights for Suba^®-Itraconazole in BCCNS

12/12/2018 Mayne Pharma receives FDA approval of Tolsura^TM 

29/10/2018 Retirement of Director

26/10/2018 Mayne Pharma Acquires FDA-Approved Halobetasol Foam, Complementing US Dermatology Portfolio

24/08/2018 Mayne Pharma FY18 Results Media Release 

30/07/2018 Mayne Pharma Launches Butalbital Acetaminophen Capsules in the United States 

23/07/2018 Mayne Pharma Acquires Generic Efudex®, Complementing US Dermatology Portfolio

16/07/2018 Mayne Pharma Launches Generic Kapvay® in the U.S.

28/06/2018 Mayne Pharma further strengthens Board with new Director

30/05/2018 Mayne Pharma strengthens Board with new Director

02/05/2018 Mayne Pharma Announces FDA Acceptance of new Drug Application for its Antifungal Suba®-Itraconazole Capsule

17/04/2018 Mayne Pharma Opens New $80-Million Oral Solid-Dose Commercial Manufacturing Facility in Greenville, North Carolina

16/04/2018 Mayne Pharma Launches Amiodarone Tablets 200mg in the United States

26/03/2018 Mayne Pharma Launches Generic Quartette® in the U.S., Another Women's Health Product

20/03/2018 Mayne Pharma’s Generic Nuvaring® Anda Accepted for Filing by FDA

15/03/2018 Mayne Pharma Launches Doxycycline IR Capsules in the US, Generic Monodox

27/02/2018 Mayne Pharma Launches First Generic Methylphenidate Extended-Release 10 MG Capsules in the United States

23/02/2018 HY18 Results Media Release (PDF)